- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03153774
Bedömningar av sarkopeniprevalens hos patienter med kronisk hjärtsvikt och hos patienter före TAVI (PRESAR-HF)
Bedömningar av sarkopeniprevalens hos patienter med kronisk hjärtsvikt och hos patienter före implantation av transkateter aortaklaff
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, Frankrike, 63003
- CHU Clermont-Ferrand
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Major patients (>18 years)
- Men or women
- Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
- Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol
Exclusion Criteria:
- Patient not affiliated to social security
- Inability to understand the information consent letter
- Not having signed informed consent
- Has a mental or legal incapacitation and is unable to provide informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Heart failure patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test |
|
Experimentell: TAVI patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Handgreppstest
Tidsram: på dag 1
|
på dag 1
|
|
|
Bioimpedance analysis data
Tidsram: at day 1
|
Fat-free mass and body fat mass will be combined to report BMI in Kg/m2 |
at day 1
|
|
Short physical performance battery
Tidsram: at day 1
|
Balance test, 4-min walking test, 5 times getting-up test |
at day 1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Blood draw for serum creatinine in umol/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
CRP in mg/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
platelets in Giga/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L)
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
urea in mmol/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
albumin in g/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
NT-ProBNP in ng/L
Tidsram: at day 1
|
Measure of inflammation |
at day 1
|
|
Electrocardiogram
Tidsram: at day 1
|
Parameter which may interfere with sarcopenia |
at day 1
|
|
Trans-thoracic echography
Tidsram: at day 1
|
Parameter which may interfere with sarcopenia |
at day 1
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Allmänna publikationer
- Blanquet M, Massoulie G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, Boiteux MD, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Rossignol P, Clerfond G, Eschalier R. Handgrip strength to screen early-onset sarcopenia in heart failure. Clin Nutr ESPEN. 2022 Aug;50:183-190. doi: 10.1016/j.clnesp.2022.05.019. Epub 2022 Jun 6.
- Eschalier R, Massoullie G, Boirie Y, Blanquet M, Mulliez A, Tartiere PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 9.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CHU-324
- 2014-A00938-39 (Annan identifierare: 2014-A00938-39)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .